Pharma's growth potential. At a CMP of ?313, the company trades at a P/E of 14.9x and EV/EBITDA of 9.6x. In contrast, Aarti Drugs, with a less attractive business model, commands a P/E of 23x and EV/EBITDA of 14.5x, highlighting value opportunities. https://threadreaderapp.com/scro